Stockreport

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal [Read more]